Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- European Regulator Accepts Mitsubishi Tanabe’s Edaravone Filing for ALS
May 29, 2018
- Takeda Sales Reps Heavily Pitch Inisync, Takecab in February: Anterio Ranking
May 28, 2018
- FDA Extends Action Date for Lenvima’s HCC Indication by 3 Months
May 28, 2018
- AbbVie Seeks Japan Approval for Psoriasis Drug Risankizumab
May 28, 2018
- Opdivo/Yervoy Combo Gains Japan Nod for Melanoma
May 28, 2018
- 3 Generic Major Companies Maintain Double-Digit Growth in FY2017: Jiho Tally
May 28, 2018
- Otsuka/Lundbeck to Launch Add’l PIII for Brexpiprazole in June
May 25, 2018
- Chugai Seeks Still’s Disease Indication for Actemra
May 25, 2018
- Maviret Top Seller Drug in Japan in January-March: IQVIA
May 23, 2018
- Astellas Eyes 1 Trillion Yen Peak Sales with 6 Late-Stage Assets: Biz Plan
May 23, 2018
- Astellas to Shed 600 Jobs to Revamp Japan Operations
May 23, 2018
- Hemlibra, MSD/Astellas’ DPP-4/SGLT2 Combo Hit Japan Market
May 23, 2018
- Top 4 Wholesalers Report Unusually Low Growth in Drug Wholesale Business for 2nd Year after Price Revision
May 23, 2018
- JCR’s Sakigake-Designated Hunter Syndrome Treatment to Enter PII/III in 1st Half of FY2018
May 23, 2018
- Janssen Files Triple-Combo for HIV Treatment in Japan
May 23, 2018
- Takeda Divests China JV Techpool
May 22, 2018
- Kyowa Kirin to Use Surrogate Endpoint in PIII Trial of Sakigake CKD Treatment; Application Could Come as Early as 2022
May 22, 2018
- AZ Files Forxiga for Expanded Use in Type 1 Diabetes in Japan
May 22, 2018
- Ethical Drug Sales Up 0.2% in FY2017: Crecon Report
May 21, 2018
- Dustin Haines Named as President of ViiV Healthcare Japan
May 21, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…